Expression of cell cycle regulatory genes in chronic myelogenous leukemia

Haematologica

Volumn 83, Issue 9, 1998, Pages 771-777

  Iolascon, Achille ^a,d   Della Ragione, Fulvio ^b   Giordani, Lucia ^a   Serra, Anna ^c   Saglio, Giuseppe ^c   Faienza, Maria Felicia ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Dipartimento di Biomedicina dell'Eta Evolutiva   (Italy)

Author keywords

CDKNI; Cell cycle; Chronic myelogenous leukemia; Leukemia; Tumor suppressor genes

Indexed keywords

ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; CELL CYCLE; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; GENE EXPRESSION; GENE STRUCTURE; HUMAN; HUMAN CELL; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BLAST CRISIS; BONE MARROW CELLS; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE PROGRESSION; ENZYME INHIBITORS; FUNGAL PROTEINS; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RETINOBLASTOMA PROTEIN; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0031733454     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current theraputic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82:478-95.
2. Santucci MA, Saglio G, Tura S. Pathogenesis and progression of chronic myeloid leukemia. Haematologica 1996; 81:63-76.
3. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497-501.
4. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
5. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9.
6. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233:212-4.
7. Bedi A, Barber JP, Bedi GC, et al. BCR/ABL mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-58.
8. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC p53 mutations in human cancer. Science 1991; 253: 49-53.
11. Benedict WF, Xu HJ, Hu SX, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990; 85:988-93.
12. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75: 1684-90.
13. Gaidano G, Serra A, Guerrasio A, Rege-Cambrin G, Mazza U, Saglio G. Genetic analysis of p53 and RB1 tumor suppressor genes in blast crisis of chronic myeloid leukemia. Ann Hematol 1994; 68:3-7.
14. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841-54.
15. Ogawa S, Hangaishi A, Myawaki S, et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86:1548-56.
16. Cordon-Cardo C. Mutation of cell-cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 1995; 147:545-60.
17. Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol 1995; 91:625-9.
18. Sill H, Goldman JM, Cross NCP. Homozygous deletions of the p16 tumor suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85, 8:2013-6.
19. Arlin ZA, Silver RT, Bennet JM. Blastic phase of chronic myeloid leukaemia (blCML): a proposal for standardization of diagnostic and response criteria. Leukaemia 1990; 4: 755-7.
20. Hirsch-Ginsberg C, Huh YO, Kagan J, Liang JC, Sass SA. Advances in the diagnosis of acute leukemia. Hemat/Oncol Clin North Am 1993; 7:1-38.
21. Serra A, Guerrasio A, Gaidano G, et al. Molecular defects associated with the acute phase CML. Leuk Lymphoma 1993; 11:25-8.
22. Della Ragione F, Borriello A, Mastropietro S, et al. Expression of G1-phase cell cycle genes during hematopoietic lineage. Biochem Biophys Res Commun 1997; 231:73-6.
23. Maniatis T, Fritsch E, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory NY, 1982.
24. Iolascon A, Faienza MF, Coppola B, Della Ragione F, Santoro N, Schettini F. High frequency of homozygous deletions of CDK4I gene in childhood acute lymphoblastic leukaemia. Br J Haematol 1995; 91:647-51.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchlorophorm extraction. Anal Biochem 1987; 162: 156-9.
26. Uchimaru K, Taniguchi T, Yoshimawa M, et al. Detection of clyclin D1 (bcl-1, Prad 1) overexpression by simple competitive reverse transcription-PCR assay in t(11;14)(q13;q32)-bearing B cell malignancies and/or mantle cell lymphoma. Blood 1997; 89:965-74.
27. Hangaishi A, Ogawa S, Imamura N, et al. Inactivation of multiple tumor suppressor genes involved in negative regulation of the cell cycle, MTS1/p16/CDKN2, MTS2/p15, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87:4949-58.
28. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
29. Cline MJ, Jat PS, Foti A. Molecular mechanisms in the evolution of chronic myelocytic leukemia. Leuk Lymphoma 1992; 7:283-7.
30. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocitic leukemia. Proc Natl Acad Sci USA 1989; 86:6783-7.
31. Ahuja H, Bar-Eli M, Arlin X, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87:2042-7.
32. INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 1997; 31:495-503.
33. Cayuela JM, Madani A, Sanhes S, Stern MH, Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87:2180-6.
34. Guidal-Giroux C, Gerard B, Cavé H, et al. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br J Haematol 1996; 92: 410-9.
35. Uchida T, Kinhoshita T, Watanabe T, et al. The CDKN2 gene alterations in various types of adult T-cell leukaemia. Br J Haematol 1996; 94:665-70.
36. Gonzales-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55:4531-5.
37. INK4B1. Cancer Res 1996; 56: 722-7.
38. Iolascon A, Giordani L, Tonini GP, Mastropietro S, Borriello A, Della Ragione F. Structural and functional analysis of cyclin dependent kinase inhibitor genes (CDKN2A, CDKN2B and CDKN2C) in neuroblastoma. Ped Res 1998; 43:139-44.
39. kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Gene Develop 1995; 9:639-49.
40. kip2 and its reduced expression in Wilms tumors. Hum Mol Genet 1996; 5:783-8.
41. Nomdedeu JF, Lete I, Baiget M, et al. Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma. Haematologica 1997; 82:550-4.